VII

Dr Ali Hammosh
Benghazi Medical University

Trade names

NovoSeven, AryoSeven

IS ONE OF THEPROTEINS
THAT CAUSES BLOOD TO
CLOT IN THE
COAGULATION CASCADE
This treatment results in
activation of the extrinsic
pathway of blood
coagulation

THEGENEFOR FACTOR VII IS

LOCATED ONCHROMOSOME13
(13Q34)
Deficiency is rare (congenital proconvertin
deficiency) and inherits recessively. Factor VII
deficiency presents as a hemophilia-like
bleeding disorder

MEDICAL USES
( -withFactor VIIIorIXdeficiency)hemophilia
It has also been used in the setting of uncontrollabletreatment and prevention from bleeding episodes in those
undergoing
:surgery or invasive procedures in the following patients
In patients with congenital haemophilia
In patients with congenital haemophilia who are expected
to have a high anamnestic response to factor VIII or factor
IX administration
In patients with acquired haemophilia
In patients with congenital FVII deficiency
In patients with Glanzmanns thrombasthenia with
antibodies to GP IIb - IIIa and/or HLA, and with past
or present refractoriness to platelet transfusions
hemorrhage
- Glanzmann's thrombasthenia

ROUTE OF ADMINISTRATION
.ADMINISTEREDINTRAVENOUSLY(IV) UNDER PHYSICIAN SUPERVISION

SIDE EFFECTS

THANX